Squeeze Risk Escalation
Novavax (NVAX) has experienced a notable shift in its market dynamics, with its squeeze score climbing from 73.5 to 84.2 in the latest reporting period. With 32.3% of its float currently sold short, the stock is exhibiting classic signs of a potential squeeze setup. The days-to-cover ratio stands at 5.3, suggesting that any significant upward price movement could force short sellers to cover, potentially exacerbating volatility. Traders are monitoring the borrow fee, which currently sits at 0.4%, to see if supply constraints emerge.
Signal data sourced from Tapeboard. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.